<?xml version="1.0" encoding="Windows-31J"?>
<ArticleSet xmlns="http://www.openarchives.org/OAI/2.0/">
  <Article>
    <Journal>
      <PublisherName>Japan Radioisotope Association</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0033-8303</Issn>
      <Volume>75</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>自然起源放射性物質（NORM）を用いた232Th/212Pbジェネレーターによる短寿命放射性核種の作製―非密封放射性同位元素の安全取扱実習への応用―</ArticleTitle>
    <FirstPage LZero="delete">13</FirstPage>
    <LastPage>19</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yui</FirstName>
        <LastName>Imada</LastName>
        <Affiliation>Advanced Science Research Center, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Midori</FirstName>
        <LastName>Isobe</LastName>
        <Affiliation>Advanced Science Research Center, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroaki</FirstName>
        <LastName>Terato</LastName>
        <Affiliation>Advanced Science Research Center, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Hanafusa</LastName>
        <Affiliation>Advanced Science Research Center, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>我々は自然起源放射性物質（NORM）を放射線源とする232Th/212Pbジェネレーターを作製した。ジェネレーターから室温で約500&#8201;Bqの高純度の212Pbをミルキングできた。これを用いて32Pを用いた非密封放射性同位元素の安全取扱実習を置き換えることができることを示した。ジェネレーターの作製の容易さ，ミルキング操作の簡便性，212Pb及びその子孫核種の放射性同位元素としての特性から，今回作製した232Th/212Pbジェネレーターは放射線教育に有効に活用できると結論した。</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">lead-212</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">radioisotope generator</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">safe handling training</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">unsealed radioisotope</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2513-0390</Issn>
      <Volume>6</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2023</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Particle and Heavy Ion Transport Code System‐Based Microdosimetry for the Development of Boron Agents for Boron Neutron Capture Therapy</ArticleTitle>
    <FirstPage LZero="delete">2300163</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Shigehira</LastName>
        <Affiliation>Department of Cellular Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Hanafusa</LastName>
        <Affiliation>Neutron Therapy Research Center, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyo</FirstName>
        <LastName>Igawa</LastName>
        <Affiliation>Neutron Therapy Research Center, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomonari</FirstName>
        <LastName>Kasai</LastName>
        <Affiliation>Neutron Therapy Research Center, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuichi</FirstName>
        <LastName>Furuya</LastName>
        <Affiliation>Research Laboratory of Accelerator-Based BNCT system, Graduate School of Engineering Nagoya University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisakazu</FirstName>
        <LastName>Nishimori</LastName>
        <Affiliation>Department of Hematology and Oncology Okayama University Hospital  Okayama Okayama 700&#8211;8558 Japan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Michiue</LastName>
        <Affiliation>Neutron Therapy Research Center, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Fujimura</LastName>
        <Affiliation>Department of Cellular Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Boron neutron capture therapy (BNCT) is a radiation therapy that selectively kills cancer cells at the cellular level using the boron neutron capture reaction (BNCR) (10B(n.α)7Li). The amount of boron 10B delivers in boronophenylalanine (BPA)-BNCT to achieve anti-tumor effects is &#8776;15&#8211;40 ppm. The same is true for all boron drugs; however, whether the same amount of 10B is required for other boron drugs with different accumulation characteristics has not been intensively investigated. Therefore, herein, a virtual cell model with intracellular organelles is prepared, and the BPA equivalent dose concentration to the cell nucleus is analyzed using particle and heavy ion transport code system-based microdosimetry. Additionally, the intranuclear minimal region (IMR) is set as a reference for the concept of the intranuclear domain in the microdosimetric kinetic model, and the BPA equivalent dose concentration to the IMR is estimated. The required boron delivery dose greatly varies depending on the dose assessment based on the accumulation characteristics of boron agents in intracellular organelles. Evaluation of the BNCR effect according to the accumulation characteristics without being influenced by the specified value of 15&#8211;40 ppm is recommended.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">boron agents</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">boron neutron capture therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">simulation study</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2073-4409</Issn>
      <Volume>9</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2020</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>In Vitro Studies to Define the Cell-Surface and Intracellular Targets of Polyarginine-Conjugated Sodium Borocaptate as a Potential Delivery Agent for Boron Neutron Capture Therapy</ArticleTitle>
    <FirstPage LZero="delete">2149</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Fujimura</LastName>
        <Affiliation>Department of Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Seiji</FirstName>
        <LastName>Yasui</LastName>
        <Affiliation>Neutron Therapy Research Center, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyo</FirstName>
        <LastName>Igawa</LastName>
        <Affiliation>Neutron Therapy Research Center, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ai</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Neutron Therapy Research Center, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaori</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Neutron Therapy Research Center, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Hanafusa</LastName>
        <Affiliation>Neutron Therapy Research Center, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuaki</FirstName>
        <LastName>Ichikawa</LastName>
        <Affiliation>Neutron Therapy Research Center, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sachiko</FirstName>
        <LastName>Yoshihashi</LastName>
        <Affiliation>Graduate School of Engineering, Nagoya University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuki</FirstName>
        <LastName>Tsuchida</LastName>
        <Affiliation>Graduate School of Engineering, Nagoya University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsunori</FirstName>
        <LastName>Kamiya</LastName>
        <Affiliation>Department of Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuichi</FirstName>
        <LastName>Furuya</LastName>
        <Affiliation>Neutron Therapy Research Center, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Boron neutron capture therapy (BNCT) requires pharmaceutical innovations and molecular-based evidence of effectiveness to become a standard cancer therapeutic in the future. Recently, in Japan, 4-borono-L-phenylalanine (BPA) was approved as a boron agent for BNCT against head and neck (H&amp;N) cancers. H&amp;N cancer appears to be a suitable target for BPA-BNCT, because the expression levels of L-type amino acid transporter 1 (LAT1), one of the amino acid transporters responsible for BPA uptake, are elevated in most cases of H&amp;N cancer. However, in other types of cancer including malignant brain tumors, LAT1 is not always highly expressed. To expand the possibility of BNCT for these cases, we previously developed poly-arginine peptide (polyR)-conjugated mercaptoundecahydrododecaborate (BSH). PolyR confers the cell membrane permeability and tumor selectivity of BSH. However, the molecular determinants for the properties are not fully understood. In this present study, we have identified the cluster of differentiation 44 (CD44) protein and translational machinery proteins as a major cell surface target and intracellular targets of BSH-polyR, respectively. CD44, also known as a stem cell-associated maker in various types of cancer, is required for the cellular uptake of polyR-conjugated molecules. We showed that BSH-polyR was predominantly delivered to a CD44(High) cell population of cancer cells. Once delivered, BSH-polyR interacted with the translational machinery components, including the initiation factors, termination factors, and poly(A)-biding protein (PABP). As a proof of principle, we performed BSH-polyR-based BNCT against glioma stem-like cells and revealed that BSH-polyR successfully induced BNCT-dependent cell death specifically in CD44(High) cells. Bioinformatics analysis indicated that BSH-polyR would be suitable for certain types of malignant tumors. Our results shed light on the biochemical properties of BSH-polyR, which may further contribute to the therapeutic optimization of BSH-BNCT in the future.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">boron neutron capture therapy (BNCT)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">BSH-polyR</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CD44</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">translational machinery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bioinformatics</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>日本アイソトープ協会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>00338303</Issn>
      <Volume>48</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>1999</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Volume Reduction by the Incineration of the Combustible Radioactive Solid Samples from Radioisotope Usage at the Utilization Facility : Estimation of the Distribution of Low Energy β-Emitter Using the Imaging Plate</ArticleTitle>
    <FirstPage LZero="delete">320</FirstPage>
    <LastPage>326</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Yumoto</LastName>
        <Affiliation>Radioisotope Center, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Hanafusa</LastName>
        <Affiliation>Radioisotope Center, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Nagamatsu</LastName>
        <Affiliation>Radioisotope Center, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeru</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Radioisotope Center, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We want to establish a system of volume reduction by the incineration of the combustible radioactive solid wastes from radioisotope usage at the utilization facility. We have been performing experiments using an experimental incineration system to examine the distribution of radionuclides during incineration and to collect basic data. To reproduce the realistic conditions of incineration of low-level radioactive wastes in an experimental system, we adopted new incineration methods in this study. Low level radioactive samples (LLRS) were set up in a mesh container of stainless steel and incinerated at high temperature (over 800&#8226;&#381;) generated by two sets of high calorie gas burners. Low energy &#402;&#192;-emitters 35S, 45Ca, 33P, and a high energy &#402;&#192;-emitter 32P were used for the experiment. Their translocation percentages in exhaust air and dust were estimated using the Imaging Plate. Distribution of radionuclides during the incineration was similar to that estimated by conventional methods by our study or to that reported in incineration of liquid scintillation cocktail waste. We concluded that the use of the Imaging Plates is a simple and reliable method for estimation of the distribution of low energy &#402;&#192;-emitters in incineration gas and ash.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">low level radioactive sample (LLRS)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">low energy β-emitter</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Imaging Plate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">experimental incineration system</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>日本アイソト-プ協会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>00338303</Issn>
      <Volume>46</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>1997</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>低レベル放射性試料の焼却実験システムの設置と燃焼実験</ArticleTitle>
    <FirstPage LZero="delete">443</FirstPage>
    <LastPage>449</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName/>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName/>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName/>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName/>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Setting up Experimental Incineration System for Low-level Radioactive Samples and Combustion Experiments. Yasuhiro YUMOTO, Tadashi HANAFUSA, Tomohiro NAGAMATSU and Shigeru OKADA: Radioisotope Center, Okayama University, 2-5-1, Shikata-cho, Okayama-shi 700, Japan.&lt;/br&gt;
An incineration system was constructed which were composed of a combustion furnace (AP-150 R), a cyclone dust collector, radioisotope trapping and measurement apparatus and a radioisotope storage room built in the first basement of the Radioisotope Center.&lt;/br&gt;
Low level radioactive samples (LLRS) used for the combustion experiment were composed of combustible material or semi-combustible material containing
500 kBq of 99mTcO4 or 23.25 kBq of 131INa. The distribution of radioisotopes both in the inside and outside of combustion furnace were estimated. We measured radioactivity of a smoke duct gas in terminal exit of the exhaust port. In case of combustion of LLRS containing 99mTcO4 or 131INa, concentration of radioisotopes at the exhaust port showed less than legal concentration limit of these radioisotopes. In cases of combustion of LLRS containing 99mTcO4 or 131INa, decontamination factors of the incineration system were 120 and 1.1, respectively.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">low level radioactive sample (LLRS)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">experimental incineration system for LLRS</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0236-5731</Issn>
      <Volume>313</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2017</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>In vitro analysis of radioprotective effect of monoterpenes</ArticleTitle>
    <FirstPage LZero="delete">169</FirstPage>
    <LastPage>174</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ken-ichi</FirstName>
        <LastName>Kudo</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Hanafusa</LastName>
        <Affiliation>Department of Radiation Research, Advanced Science Research CenterOkayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiro</FirstName>
        <LastName>Ono</LastName>
        <Affiliation>Department of Radiation Research, Advanced Science Research CenterOkayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract> Monoterpenes are naturally occurring hydrocarbons composed of two units of isoprenes. They exhibit antioxidant activity to scavenge reactive oxygen species, such as hydroxyl radicals. We investigated the potential of monoterpenes such as thymol, linalool, and menthol to act as radioprotectants. The proliferation of EL4 cells, a mouse lymphoma cell line, treated with linalool at a concentration of 500 μM or more was not affected by X-ray irradiation. Plasmid-nicking assay performed using formamidopyrimidine-DNA glycosylase showed that linalool prevented single strand breaks and oxidized purines on pUC19 plasmid DNA. These findings indicate that linalool has the ability to scavenge reactive oxygen species and is a potential radioprotector.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Monoterpenes</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value"> Linalool </Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">X-ray irradiation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value"> Reactive oxygen species</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value"> SSB </Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Netherlands</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0236-5731</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2015</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Adsorption and removal of strontium in aqueous solution by synthetic hydroxyapatite</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuichi</FirstName>
        <LastName>Nishiyama</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Hanafusa</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoko</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiro</FirstName>
        <LastName>Ono</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Hydroxyapatite (HAP) is a main mineral constituent of bone and tooth and has an outstanding biocompatibility. HAP is a possible sorbent for heavy metals in wastewater due to its high adsorption capacity and low water solubility. We developed a removal system of 90Sr from aqueous solution by HAP column procedure. More than 90 % of 90Sr was adsorbed and removed from the 90Sr containing solution. Divalent cations, Ca2+, had little effect on the removal of 90Sr up to a concentration of 1 mmol L−1. This clearly indicates that the HAP column technique is advantageous with respect to the capacity to adsorb 90Sr from water present in the environment.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Strontium</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hydroxyapatite</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Adsorption</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Desorption</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Divalent cation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier Ireland Ltd.</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0304-3835</Issn>
      <Volume>301</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2011</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Isolation and characterization of human lung cancer antigens by serological screening with autologous antibodies</ArticleTitle>
    <FirstPage LZero="delete">57</FirstPage>
    <LastPage>62</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Hanafusa</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ali Eldib Ali</FirstName>
        <LastName>Mohamed</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Kitaoka</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Ohue</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiichi</FirstName>
        <LastName>Nakayama</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiro</FirstName>
        <LastName>Ono</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Serological analysis of a recombinant cDNA expression library (SEREX) derived from two lung adenocarcinoma cancer cell lines using autologous sera led to the isolation of 41 positive cDNA clones comprising 28 different antigens. They coded for a variety of nuclear and cytoplasmic proteins. Among the antigens, nucleoporin 107 (NUP107) was isolated most frequently (5 of 41 clones). The second most frequently isolated antigen was coded for by C21orf58 (4 of 41 clones). During serological analysis of selected antigens based on their reactivity to sera from normal individuals and lung cancer patients, none of the antigens showed a cancer-restricted recognition pattern. However, five genes including NUP107 showed higher expression when we examined the changes in gene expression in five different adenocarcinoma cell lines, including those used in SEREX, compared with their levels in normal lung tissues by cDNA microarray analysis. On the other hand, the expression levels of five genes including C21orf58 were down regulated in all adenocarcinoma cell lines. This SEREX study combining comprehensive gene expression assays has added to the growing list of lung cancer antigens, which may aid the development of diagnostic and immunotherapeutic reagents for patients with lung cancer.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Lung adenocarcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">SEREX</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tumor antigen</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">NUP107</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">MYL6B</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>46</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>1992</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Detection by western blotting of an antibody to the hepatitis C virus E1 envelope protein in sera of patients with chronic liver disease.</ArticleTitle>
    <FirstPage LZero="delete">367</FirstPage>
    <LastPage>370</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hajime</FirstName>
        <LastName>Hada</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norio</FirstName>
        <LastName>Koide</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Hanafusa</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosaku</FirstName>
        <LastName>Sakaguchi</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Shinji</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Sasaki</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiko</FirstName>
        <LastName>Oka</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Niro</FirstName>
        <LastName>Takayama</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Yumoto</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType>Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">/10.18926/AMO/32656</ArticleId>
    </ArticleIdList>
    <Abstract>&lt;p&gt;We detected an antibody to HCV envelope protein (E1) in sera of patients with HCV-related chronic liver diseases (20 patients with chronic hepatitis and 5 patients with liver cirrhosis) by Western blotting using the fusion protein of E1 envelope protein and beta-galactosidase as an antigen. The antibody to HCV E1 (anti-HCV E1) was detected in 8 (42%) of 19 patients positive for HCV-RNA (16 were positive and 3 were negative for antibody to C100-3) and in 1 (17%) of 6 patients negative for HCV-RNA but positive for antibody to C100-3. HCV-RNA was detected in 8 (89%) of 9 anti-HCV E1 positive sera. The value of alanine aminotransferase was significantly higher in patients positive for anti-HCV E1 than in patients negative for the antibody. Although an antibody to the envelope protein of HCV is suspected to be one of the candidates of virus-neutralizing antibodies, our results suggest this hypothesis appears to be unlikely.&lt;/p&gt;</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">hepatitis C virus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">envelope</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">antibody</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Western blotting</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>45</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>1991</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Sequence variations in the envelope protein of the hepatitis C virus: comparison with partial cDNA sequence of a new variant virus obtained by the polymerase chain reaction.</ArticleTitle>
    <FirstPage LZero="delete">347</FirstPage>
    <LastPage>355</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hajime</FirstName>
        <LastName>Hada</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norio</FirstName>
        <LastName>Koide</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Takabatake</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Hanafusa</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType>Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">/10.18926/AMO/32196</ArticleId>
    </ArticleIdList>
    <Abstract>It has been reported that the envelope region located at the 3' portion of the structural protein coding region is one of the most variable regions at both nucleotide and amino acid sequence levels in the hepatitis C virus (HCV) genome. We cloned HCV cDNA fragments of an envelope protein coding region (HCVNK), which were derived from serum of a Japanese patient with hepatocellular carcinoma and were amplified by polymerase chain reaction. After determining the nucleotide sequence, deduced amino acid sequence of the envelope protein region was compared with those of six HCV strains already published (HCJ1, HCVUS, HCJ4, HCVJH, HCVJ and HCVBK). Homology analysis among the strains revealed that the seven strains were classified into two subtypes; a US subtype (HCJ1 and HCVUS) and a Japanese subtype (HCJ4, HCVJH, HCVJ, HCVBK and HCVNK), since percentage homologies between two subtypes (70.3-77.3%) were significantly lower than those within each subtype (83.9-93.5%). Detailed analysis of the amino acid sequences also indicates that the region at aa246-aa258, tentatively named intersubtype variable region-1, may distinguish the US subtype from the Japanese subtype.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">hapatitis C virus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">envelope</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">DNA sequecing</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">homology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">intersubtype variable region</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>BioMed Central</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1471-2407</Issn>
      <Volume>5</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2005</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Functional promoter upstream p53 regulatory sequence of IGFBP3 that is silenced by tumor specific methylation</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Hanafusa</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Shinji</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidenori</FirstName>
        <LastName>Shiraha</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Nouso</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiaki</FirstName>
        <LastName>Iwasaki</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eichiro</FirstName>
        <LastName>Yumoto</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiro</FirstName>
        <LastName>Ono</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norio</FirstName>
        <LastName>Koide</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>&lt;p&gt;&lt;b&gt;Background:&lt;/b&gt; Insulin-like growth factor binding protein (IGFBP)-3 functions as a carrier of insulinlike
growth factors (IGF&lt;sub&gt;s&lt;/sub&gt;) in circulation and a mediator of the growth suppression signal in cells. There are two reported p53 regulatory regions in the IGFBP3 gene; one upstream of the promoter and one intronic. We previously reported a hot spot of promoter hypermethylation of IGFBP-3 in
human hepatocellular carcinomas and derivative cell lines. As the hot spot locates at the putative upstream p53 consensus sequences, these p53 consensus sequences are really functional is a question to be answered.&lt;br /&gt;
&lt;b&gt;Methods:&lt;/b&gt; In this study, we examined the p53 consensus sequences upstream of the IGFBP-3 promoter for the p53 induced expression of IGFBP-3. Deletion, mutagenesis, and methylation
constructs of IGFBP-3 promoter were assessed in the human hepatoblastoma cell line HepG2 for promoter activity.&lt;br /&gt;
Results: Deletions and mutations of these sequences completely abolished the expression of IGFBP-3 in the presence of p53 overexpression. In vitro methylation of these p53 consensus
sequences also suppressed IGFBP-3 expression. In contrast, the expression of IGFBP-3 was not affected in the absence of p53 overexpression. Further, we observed by electrophoresis mobility
shift assay that p53 binding to the promoter region was diminished when methylated.&lt;br /&gt;
&lt;b&gt;Conclusion:&lt;/b&gt; From these observations, we conclude that four out of eleven p53 consensus sequences upstream of the IGFBP-3 promoter are essential for the p53 induced expression of
IGFBP-3, and hypermethylation of these sequences selectively suppresses p53 induced IGFBP-3 expression in HepG2 cells.&lt;/p&gt;</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山大学環境管理センター</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0917-1533</Issn>
      <Volume>30</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2008</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>岡山大学における核燃料物質の安全管理のための劣化ウランと天然ウランの鑑別について</ArticleTitle>
    <FirstPage LZero="delete">33</FirstPage>
    <LastPage>37</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Nagamatsu</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Hanafusa</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ikuo</FirstName>
        <LastName>Kinno</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Sakoda</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsumi</FirstName>
        <LastName>Hanamoto</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyonori</FirstName>
        <LastName>Yamaoka</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiro</FirstName>
        <LastName>Ono</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>In Japan, the Law for the Regulation of Nuclear Source Materials, Nuclear Fuel Materials and Reactors (Regulation Law) controls the nuclear fuel materials such as thorium (Th), uranium (U) and plutonium (Pu). Under the Regulation Law, all related materials and reactors are needed to register to the Government. In Okayama University, many nuclear fuel materials, mainly uranium compounds, are registered and stored in 11 departments, separately. Discrimination between depleted uranium and natural uranium is important for the observance of the Regulation Law and the safety management of the nuclear fuel materials in the Okayama University. However, the discrimination of the two kind of uranium has poorly analyzed. In this study, we analyzed several uranium compounds by using γ-ray spectrometry to determine whether the depleted uranium or not.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Nuclear Fuel Materials</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Depleted Uranium</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Natural Uranium</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">γ-ray Spectrometry</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>1989</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Positive and negative regulation in expression of an Escherichia coli K-1'2 flagellin gene</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName/>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
</ArticleSet>
